Search Orphan Drug Designations and Approvals
-
Generic Name: | half-life extended bispecific T-cell engager antibody construct targeting MUC17 and CD3 |
---|---|
Date Designated: | 06/02/2020 |
Orphan Designation: | Treatment of gastric cancer, including cancer of gastroesophageal junction |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Amgen Inc. One Amgen Center Drive Mail Stop 27-2-D Thousand Oaks, California 91320 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-